Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapies

Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapies

Bibliographic Details
Main Authors:	Hess, Michael, Stritzker, Jochen, Härtl, Barbara, Sturm, Julia B, Gentschev, Ivaylo, Szalay, Aladar A
Format:	Online
Language:	English
Published:	BioMed Central 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3207905/

Similar Items

Oncolytic Virotherapy of Canine and Feline Cancer
by: Gentschev, Ivaylo, et al.
Published: (2014)

Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients
by: Patil, Sandeep S, et al.
Published: (2012)

Virotherapy of Canine Tumors with Oncolytic Vaccinia Virus GLV-1h109 Expressing an Anti-VEGF Single-Chain Antibody
by: Patil, Sandeep S., et al.
Published: (2012)

Preferential Colonization of Metastases by Oncolytic Vaccinia Virus Strain GLV-1h68 in a Human PC-3 Prostate Cancer Model in Nude Mice
by: Donat, Ulrike, et al.
Published: (2012)

Imaging of Intratumoral Inflammation during Oncolytic Virotherapy of Tumors by 19F-Magnetic Resonance Imaging (MRI)
by: Weibel, Stephanie, et al.
Published: (2013)

Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer
by: Weibel, Stephanie, et al.
Published: (2013)

ONCOLYTIC VIROTHERAPY
by: Russell, Stephen J, et al.
Published: (2012)

Characterization of Metastasis Formation and Virotherapy in the Human C33A Cervical Cancer Model
by: Donat, Ulrike, et al.
Published: (2014)

Oncolytic Virotherapy for Hematological Malignancies
by: Bais, Swarna, et al.
Published: (2012)

Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy
by: Adelfinger, Marion, et al.
Published: (2015)

Oncolytic virotherapy for advanced liver tumours
by: Chang, Ju-Fang, et al.
Published: (2009)

Preclinical Evaluation of Oncolytic Vaccinia Virus for Therapy of Canine Soft Tissue Sarcoma
by: Gentschev, Ivaylo, et al.
Published: (2012)

Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virotherapy
by: Haddad, Dana, et al.
Published: (2016)

Oncolytic Virotherapy for Multiple Myeloma: Past, Present, and Future
by: Thirukkumaran, Chandini M., et al.
Published: (2011)

Targeting Pediatric Cancer Stem Cells with Oncolytic Virotherapy
by: Friedman, Gregory K., et al.
Published: (2012)

Exploiting tumor epigenetics to improve oncolytic virotherapy
by: Forbes, Nicole E., et al.
Published: (2013)

Functional genomic screening to enhance oncolytic virotherapy
by: Mahoney, D J, et al.
Published: (2013)

Oncolytic virotherapy for pediatric malignancies: future prospects
by: Waters, Alicia M, et al.
Published: (2016)

MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy
by: Ruiz, Autumn J., et al.
Published: (2016)

The use of the NIS reporter gene for optimizing oncolytic virotherapy
by: Miller, Amber, et al.
Published: (2016)

Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm
by: Guan, Mingxu, et al.
Published: (2014)

Emerging role of Natural killer cells in oncolytic virotherapy
by: Bhat, Rauf, et al.
Published: (2015)

On the potential of oncolytic virotherapy for the treatment of canine cancers
by: MacNeill, Amy L
Published: (2015)

Oncolytic virotherapy for human malignant mesothelioma: recent advances
by: Boisgerault, Nicolas, et al.
Published: (2015)

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy
by: Nakashima, Hiroshi, et al.
Published: (2015)

Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy
by: Binz, Eike, et al.
Published: (2015)

Efficient Colonization and Therapy of Human Hepatocellular Carcinoma (HCC) Using the Oncolytic Vaccinia Virus Strain GLV-1h68
by: Gentschev, Ivaylo, et al.
Published: (2011)

Oncolytic Viruses
by: Chen, Nanhai G., et al.
Published: (2012)

Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68
by: Ehrig, Klaas, et al.
Published: (2013)

Evaluation of a New Recombinant Oncolytic Vaccinia Virus Strain GLV-5b451 for Feline Mammary Carcinoma Therapy
by: Adelfinger, Marion, et al.
Published: (2014)

Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy
by: Muik, Alexander, et al.
Published: (2012)

Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice
by: Auffinger, Brenda, et al.
Published: (2013)

Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy
by: Friedman, Gregory K., et al.
Published: (2013)

Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer
by: Nguyen, Andrew, et al.
Published: (2014)

Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1
by: Moehler, Markus, et al.
Published: (2014)

Thyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapy
by: Guan, Mingxu, et al.
Published: (2016)

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
by: Simpson, Guy R, et al.
Published: (2016)

Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer
by: Francis, Lily, et al.
Published: (2016)

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
by: Turnbull, Samantha, et al.
Published: (2015)

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
by: Marchini, Antonio, et al.
Published: (2016)